Introduction Chronic myeloid leukemia is a cancer originating in the bone marrow that is characterized by uncontrolled growth of myeloid white blood cells. The source of this cancer is a genetic mutation in the Philadelphia chromosome, where a translocation between chromosomes 9 and 22 causes the production of the BCR-ABL1 gene sequence. Tyrosine kinase inhibitors, like imatinib mesylate, changed chronic myeloid leukemia treatment but have several ocular side effects, such as periorbital edema. Case Report A 64-year-old Black woman presented with worsening dry eye symptoms and periorbital edema after 1 year of treatment for chronic myeloid leukemia with imatinib mesylate. The patient discussed complications with their oncologist and nephrologist. When the patient returned for a follow-up examination in 3 months, she presented with a reduction of periorbital edema after switching to bosutinib, a second-generation tyrosine kinase inhibitor, along with a improvement in the severity of her dry eye symptoms. Conclusion Chronic myeloid leukemia has more options for treatment, such as tyrosine kinase inhibitors. Learning the side effects of new cancer medications is important when evaluating a patient. Because there are several potential causes of periorbital edema, evaluating a patient’s case history is important for determining why they are experiencing this symptom.
Moskaliuk et al. (Mon,) studied this question.